Table 1.
Patients characteristics
| All patients (64) N (%) | Abiraterone group (50) N (%) | Enzalutamide group (14) N (%) | |
|---|---|---|---|
|
| |||
| Age | |||
| Median (range), years | 71 (61–92) | 73(61–87) | 69(62–92) |
| ≥ 75 years | 29 (45.3) | 24 (48.0) | 5 (35.7) |
|
| |||
| Disease at the time of diagnosis | |||
| Metastatic | 26 (40.6) | 18 (36.0) | 8 (57.1) |
| Localized | 38 (59.4) | 32 (64.0) | 6 (42.9) |
|
| |||
| Gleason score (GS) | |||
| GS 6–7 | 33 (51.6) | 27 (54.0) | 6 (42.9) |
| GS 8–10 | 31 (48.4) | 23 (46.0) | 8 (57.1) |
|
| |||
| Primary local treatment | |||
| Radical prostatektomy | 11 (17.2) | 9 (18.0) | 2 (14.3) |
| Radical radiotherapy | 36 (56.3) | 30 (60.0) | 6 (42.9) |
|
| |||
| Metastases localization | |||
| Bone | 53 (82.8) | 39 (78.0) | 14 (100.0) |
| Lymphatic | 28 (43.8) | 24 (48.0) | 4 (28.6) |
| Visceral | 2 (3.1) | 1 (2.0) | 1 (7.1) |
|
| |||
| Duration of primary ADT | |||
| Median (range), months | 23.0 (6–120) | 20.5 (6–120) | 26.5(8–120) |
|
| |||
| Performance status (PS ECOG) | |||
| PS 0 | 31 (48.4) | 24 (48.0) | 7 (50.0) |
| PS 1 | 33 (51.6) | 26 (52.0) | 7 (50.0) |
|
| |||
| Pretreatment PSA | |||
| Median (range) [ng/ml] | 20.7 (0.3–1588) | 20.1 (0.3–1588) | 21.6 (0.9–1153) |
ADT — androgen deprivation therapy; ECOG — Eastern Cooperative Oncology Group; PSA — prostate-specific antigen